Because the percentage of CD44+/CD24- cells in breast cancer cell lines does not predict tumorigenic potential, we next considered whether adding ESA to the repertoire of cell surface markers could enrich for tumor initiation capacity, as was previously demonstrated [2]. The gene discussed is CD44; the disease is breast cancer.